{"id":"metformin-empagliflozin-insulin-glargine","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Hypoglycemia"},{"rate":"null","effect":"Ketoacidosis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Metformin's action on the liver and insulin sensitivity helps to lower blood glucose levels. Empagliflozin's inhibition of SGLT2 reduces glucose reabsorption in the kidneys, also lowering blood glucose levels. Insulin glargine, a long-acting insulin analog, helps to regulate blood sugar levels by providing a steady supply of insulin.","oneSentence":"Metformin works by decreasing glucose production in the liver and increasing insulin sensitivity, while empagliflozin inhibits SGLT2 to reduce glucose reabsorption in the kidneys, and insulin glargine is a long-acting insulin analog that helps lower blood sugar levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:57.171Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"},{"name":"Chronic kidney disease"}]},"trialDetails":[{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT05040087","phase":"NA","title":"Changing the Natural History of Type 2 Diabetes (\"CHANGE\" Study)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foundation for Atlanta Veterans Education and Research, Inc.","startDate":"2021-09-01","conditions":"Type 2 Diabetes","enrollment":127},{"nctId":"NCT05161429","phase":"","title":"BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 2","enrollment":550000},{"nctId":"NCT05545800","phase":"PHASE3","title":"Efficacy and Safety Of Different Regimens In Patients With Type 2 Diabetes Receiving Intensive Insulin Therapy","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-09-01","conditions":"Type 2 Diabetes Mellitus","enrollment":78},{"nctId":"NCT05103306","phase":"","title":"Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy","status":"UNKNOWN","sponsor":"Chungbuk National University Hospital","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 2","enrollment":300},{"nctId":"NCT04027023","phase":"PHASE4","title":"Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus","status":"UNKNOWN","sponsor":"Sciema UG","startDate":"2019-10-30","conditions":"Diabetes Mellitus, Type 2","enrollment":9},{"nctId":"NCT02846233","phase":"NA","title":"Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2016-08","conditions":"Type 2 Diabetes Mellitus","enrollment":22},{"nctId":"NCT02752113","phase":"PHASE3","title":"Effects of Empagliflozin + Linagliptin vs Metformin + Insulin Glargine on Renal and Vascular Changes in Type 2 Diabetes","status":"COMPLETED","sponsor":"Institut für Pharmakologie und Präventive Medizin","startDate":"2016-04","conditions":"Diabetes Mellitus Type 2","enrollment":101},{"nctId":"NCT01011868","phase":"PHASE2","title":"Efficacy and Safety of BI 10773 in Combination With Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-11","conditions":"Diabetes Mellitus, Type 2","enrollment":494}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3490,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"metformin+empagliflozin+insulin glargine","genericName":"metformin+empagliflozin+insulin glargine","companyName":"Xiangya Hospital of Central South University","companyId":"xiangya-hospital-of-central-south-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metformin works by decreasing glucose production in the liver and increasing insulin sensitivity, while empagliflozin inhibits SGLT2 to reduce glucose reabsorption in the kidneys, and insulin glargine is a long-acting insulin analog that helps lower blood sugar levels. Used for Type 2 diabetes, Chronic kidney disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}